• If you are wondering whether Abbott Laboratories is attractively priced at around US$112.65 today, you are not alone. This article is here to unpack what that price could mean for long term investors.
• The stock has had mixed returns, with a 1.3% decline over the last 7 days, a 1.6% gain over the last 30 days, and longer term returns of a 9.3% decline year to date, a 16.5% decline over 1 year, 21.7% over 3 years, and 4.5% over 5 years.
• Recent headlines around Abbott have focused on its position as a large healthcare name, ongoing product approvals, and its role in medical devices and diagnostics. These factors all shape how investors think about its prospects and risk profile, and help frame why some investors are reassessing what they are willing to pay for the shares today.
• On our valuation checks Abbott Laboratories currently scores 4 out of 6 for being potentially undervalued. Next we will break down the key valuation methods behind that score, then finish with a more complete way to think about value that goes beyond any single model.

Approach 1: Abbott Laboratories Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a company could be worth by projecting its future cash flows and discounting them back to today’s value. It is essentially asking what those future dollars from the business are worth in today’s terms.

For Abbott Laboratories, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is about $7.26b. Based on analyst inputs for the next few years, and then extending those trends further out, Simply Wall St projects free cash flow of $16.87b in 2035, with intermediate points such as $8.93b in 2026 and $11.03b in 2028. These later year numbers are extrapolated beyond the period where analysts typically provide detailed estimates.

When those projected cash flows are discounted back, the model arrives at an estimated intrinsic value of about $155.09 per share. Compared with the recent share price of around $112.65, this DCF suggests Abbott Laboratories stock is trading at roughly a 27.4% discount, which in this model is interpreted as undervalued.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Abbott Laboratories is undervalued by 27.4%. Track this in your watchlist or portfolio, or discover 46 more high quality undervalued stocks.

Approach 2: Abbott Laboratories Price vs Earnings

For profitable companies, the P/E ratio is a useful check because it links what you pay for each share directly to the earnings that support that share. It helps you see how much investors are currently willing to pay for one dollar of earnings.

What counts as a “normal” P/E depends on how the market views a company’s growth potential and risk. Higher expected growth or lower perceived risk can justify a higher multiple, while slower growth or higher risk often means a lower one is more reasonable.

Abbott Laboratories currently trades on a P/E of 30.12x. That sits above the Medical Equipment industry average P/E of about 27.69x, but below the peer group average of 41.69x. Simply Wall St also calculates a proprietary “Fair Ratio” of 40.50x, which is the P/E level it expects given factors such as earnings growth, profit margin, industry, market cap and company specific risks.

This Fair Ratio is more tailored than a simple comparison against industry or peers because it folds multiple drivers into a single benchmark rather than relying on broad averages. Since Abbott’s actual P/E of 30.12x is below the Fair Ratio of 40.50x, this approach suggests that the shares may be trading at a lower valuation relative to their earnings than this benchmark implies.

Result: Potentially undervalued based on this metric

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Abbott Laboratories Narrative

Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives, which are simply your own story about Abbott Laboratories that links what you believe about its business to a set of forecasts and a Fair Value you can compare with the current share price.

On Simply Wall St’s Community page, Narratives are an easy tool that let you plug in assumptions like future revenue, earnings and margins, see how those flow into a forecast and Fair Value, and then decide how you might act when Fair Value sits above or below today’s price.

Because Narratives update automatically when new information such as earnings or news is added to the platform, your story and Fair Value estimate stay aligned with the latest data rather than a one off snapshot.

For Abbott Laboratories, for example, one investor on the platform currently has a Fair Value of about US$113.88 per share while another has US$133.39, which shows how two people can look at the same company, plug in different assumptions, and end up with different but clearly structured views on what the stock is worth.

Do you think there's more to the story for Abbott Laboratories? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.